Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 3/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156928 | 0.89 | TPSAB1 (0.36) | UBE2MDCUN1D1F10 | |
| SCHEMBL6156645 | 0.88 | F10 (0.48) | TRPV1F10 | |
| SCHEMBL6156424 | 0.83 | LMNA (0.37) | TRPV1LMNAHPGDTSHRF10 | |
| SCHEMBL5166370 | 0.79 | F10 (0.54) | F10 | |
| Hydrochloric Acid SCHEMBL27601426 | 0.79 | F10 (0.53) | F10 | |
| SCHEMBL6157569 | 0.77 | TP53 (0.38) | LMNAHPGDTSHRF10SMN1; SMN2 | |
| SCHEMBL6156474 | 0.77 | F10 (0.47) | UBE2MDCUN1D1F10 | |
| SCHEMBL6156018 | 0.76 | S1PR1 (0.37) | TRPV1LMNAHPGDTSHRSMN1; SMN2 | |
| SCHEMBL6159517 | 0.75 | F10 (0.37) | LMNAHPGDTSHRF10SMN1; SMN2 | |
| SCHEMBL6156664 | 0.75 | TP53 (0.40) | LMNAHPGDTSHRF10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| EP-1501814-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003093254-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2003-11-13 | — | — | WO | claimed |
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1501814-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093254-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | SERPINC1, F11, F12 | TRPV1 3373/4885LMNA 1705/4885HPGD 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.